Trial Profile
A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg (Hydrocodone 5 mg/Acetaminophen 325 mg/Promethazine 12.5 mg) as a Treatment for Moderate-to-Severe Acute Pain and the Prevention of Opioid-Induced Nausea and Vomiting (OINV) Following Orthopedic Surgery)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Mar 2023
Price :
$35
*
At a glance
- Drugs Promethazine/hydrocodone/paracetamol (Primary) ; Hydrocodone/paracetamol
- Indications Acute pain; Nausea and vomiting
- Focus Registrational; Therapeutic Use
- Sponsors Charleston Laboratories
- 02 Jan 2019 Status changed from active, no longer recruiting to completed.
- 10 Sep 2018 New trial record